High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology
- 주제(키워드) Uterine Cervical Neoplasms , Cancer Screening Tests , Human Papillomavirus DNA Tests
- 주제(기타) Oncology; Obstetrics & Gynecology
- 설명문(일반) [Kong, Tae-Wook] Ajou Univ, Dept Obstet & Gynecol, Div Gynecol Oncol, Sch Med, Suwon, South Korea; [Kim, Miseon] CHA Univ, CHA Gangnam Med Ctr, Dept Obstet & Gynecol, Sch Med, 566 Nonhyeon Ro, Seoul 06135, South Korea; [Kim, Young-Han] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Kim, Yong Beom; Hong, Joon-Seok] Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, Seongnam, South Korea; [Kim, Jayeon] CHA Univ, CHA Seoul Fertil Ctr, Dept Obstet & Gynecol, Sch Med, Seoul, South Korea; [Kim, Jae-Weon] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Park, Mi Hye] Ewha Womans Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Park, Joo Hyun] Yonsei Univ, Gangnam Severance Hosp, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Rhee, Jeong Ho] Keimyung Univ, Dept Obstet & Gynecol, Sch Med, Daegu, South Korea; [Lim, Myong Cheol] Res Inst & Hosp, Canc Healthcare Res Branch, Natl Canc Ctr, Goyang, South Korea; [Lim, Myong Cheol] Res Inst & Hosp, Ctr Uterine Canc, Natl Canc Ctr, Goyang, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 Green Published, gold
- 발행기관 KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000165973
- 본문언어 영어
- Published As http://dx.doi.org/10.3802/jgo.2020.31.e31
- PubMed https://pubmed.ncbi.nlm.nih.gov/31789003
초록/요약
Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.
more